환자 유래 이종이식(PDX) 모델 시장 - 세계 시장 규모, 점유율, 동향 분석, 기회, 예측 보고서(2019-2029년)

Global Patient-Derived Xenograft (PDX) Model Market Size More Than Doubles to Touch USD 655 Million by 2029.

Global patient-derived xenograft (PDX) model market is flourishing because of the rising demand for personalized medicine and growing cancer incidence.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global patient-derived xenograft (PDX) model market size at USD 312.56 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global patient-derived xenograft (PDX) model market size to grow at a significant CAGR of 13.1% reaching a value of USD 654.91 million by 2029. Major growth drivers for the global patient-derived xenograft model market include an increasing cancer case, heightened pharmaceutical R&D, and rising demand for personalized medicines with continued support from public and private sectors for cancer research. Adherence to the US FDA Good Manufacturing Practices (GMPs) is crucial in preclinical development. Governments' initiatives, like Small Business Innovative Research and Small Business Technology Transfer Grants, offer financial support and guidance for preclinical programs. Anticipated PDX model demand is rising globally, simplifying model selection and in vivo efficacy trials. The PDX model involves direct implantation of patient tumor tissue into immune-compromised animals, preserving vital cell-tumor interactions and proving valuable in preclinical drug testing and biomarker discovery. The introduction of immunodeficient rats will facilitate PDX models in rats. Expanding R&D activities and consistent government and private sector support for cancer research drive market growth. However, high cost and technical expertise and ethical concerns are anticipated to restrain the overall market growth during the period in analysis.

Global Patient-Derived Xenograft (PDX) Model Market - Overview

The global patient-derived xenograft (PDX) model market refers to the market encompassing the use of specialized laboratory mice or other animals to implant human tumor tissues. These PDX models are created by directly transplanting cancerous tissue from a patient into an immune-deficient animal, preserving the essential interactions between human cancer cells and the surrounding microenvironment. They serve as vital tools for preclinical research in oncology, allowing scientists and researchers to study the behavior of human tumors in a more clinically relevant setting. The market includes the development, utilization, and supply of PDX models to facilitate drug testing, biomarker discovery, and co-clinical investigations in the quest for more effective cancer treatments and personalized medicine.

Impact of COVID-19 on Global Patient-derived xenograft (PDX) model Market

COVID-19 pandemic adversely affected the global patient-derived xenograft (PDX) model market. With lockdowns, restrictions on laboratory operations, and supply chain interruptions, research activities were temporarily halted or delayed. Access to resources and animal models required for PDX model development became constrained. Furthermore, prioritization of COVID-19 research led to a diversion of resources and funding. However, as the pandemic highlighted the importance of personalized medicine, it also emphasized the significance of PDX models in cancer research. As restrictions eased, the market rebounded, driven by the growing need for innovative cancer treatments and therapies.

Global Patient-Derived Xenograft (PDX) Model Market - By Tumor Type

Based on tumor type, the global patient-derived xenograft (PDX) model market is divided into Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, Urological Tumor Models, and Hematological Tumor Models segments. The respiratory tumor model segment holds the highest share in the global patient derived xenograft model market by tumor type, due to the increased prevalence of respiratory cancers worldwide, leading to a heightened focus on developing models to study these tumors. Lung cancer, for instance, remains a leading cause of cancer-related deaths globally, necessitating a robust platform for research. PDX models for respiratory tumors enable researchers to closely mimic and study these cancers in vivo, facilitating the development of innovative therapies and treatment strategies. This growing demand for effective respiratory tumor models propels the segment's dominance in the global PDX model market.

Competitive Landscape

Major players operating in the global patient-derived xenograft (PDX) model market include: JSR Corporation, Wuxi Apptec, The Jackson Laboratory, Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Oncodesign Precision Medicine, Inotiv, Inc., Pharmatest Services, Hera BioLabs, EPO Berlin-Buch GmbH, Xentech, Urosphere, Altogen Labs, and Abnova Corporation. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Patient-Derived Xenograft (PDX) Model Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Patient-Derived Xenograft (PDX) Model Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Patient-Derived Xenograft (PDX) Model Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Rising demand for personalized medicine
    • 3.2.1.2. Growing cancer incidence
  • 3.2.2. Restraints
    • 3.2.2.1. High cost and technical expertise
    • 3.2.2.2. Ethical concerns
  • 3.2.3. Opportunities
    • 3.2.3.1. Expansion in research and development
    • 3.2.3.2. Collaborations and partnerships
  • 3.2.4. Challenges
    • 3.2.4.1. Model variability
    • 3.2.4.2. Regulatory hurdles
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Patient-Derived Xenograft (PDX) Model Market Overview

• 4.1. Market Size & Forecast, 2019-2029
  • 4.1.1. By Value (USD Million)
• 4.2. Market Share and Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Mice Model
    • 4.2.1.2. Rats Model
  • 4.2.2. By Tumor Type
    • 4.2.2.1. Gastrointestinal Tumor Model
    • 4.2.2.2. Gynecological Tumor Model
    • 4.2.2.3. Respiratory Tumor Model
    • 4.2.2.4. Urological Tumor Models
    • 4.2.2.5. Hematological Tumor Models
    • 4.2.2.6. Others
  • 4.2.3. By End User
    • 4.2.3.1. Pharmaceutical & Biotechnology Companies
    • 4.2.3.2. Academic & Research Institutions
    • 4.2.3.3. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia Pacific (APAC)
    • 4.2.4.4. Latin America (LATAM)
    • 4.2.4.5. Middle East and Africa (MEA)

5. North America Patient-Derived Xenograft (PDX) Model Market

• 5.1. Market Size & Forecast, 2019-2029
  • 5.1.1. By Value (USD Million)
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Tumor Type
  • 5.2.3. By End User
  • 5.2.4. By Country
    • 5.2.4.1. United States
    • 5.2.4.1.1. By Type
    • 5.2.4.1.2. By Tumor Type
    • 5.2.4.1.3. By End User
    • 5.2.4.2. Canada
    • 5.2.4.2.1. By Type
    • 5.2.4.2.2. By Tumor Type
    • 5.2.4.2.3. By End User

6. Europe Patient-Derived Xenograft (PDX) Model Market

• 6.1. Market Size & Forecast, 2019-2029
  • 6.1.1. By Value (USD Million)
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Tumor Type
  • 6.2.3. By End User
  • 6.2.4. By Country
    • 6.2.4.1. Germany
    • 6.2.4.1.1. By Type
    • 6.2.4.1.2. By Tumor Type
    • 6.2.4.1.3. By End User
    • 6.2.4.2. United Kingdom
    • 6.2.4.2.1. By Type
    • 6.2.4.2.2. By Tumor Type
    • 6.2.4.2.3. By End User
    • 6.2.4.3. Italy
    • 6.2.4.3.1. By Type
    • 6.2.4.3.2. By Tumor Type
    • 6.2.4.3.3. By End User
    • 6.2.4.4. France
    • 6.2.4.4.1. By Type
    • 6.2.4.4.2. By Tumor Type
    • 6.2.4.4.3. By End User
    • 6.2.4.5. Spain
    • 6.2.4.5.1. By Type
    • 6.2.4.5.2. By Tumor Type
    • 6.2.4.5.3. By End User
    • 6.2.4.6. Belgium
    • 6.2.4.6.1. By Type
    • 6.2.4.6.2. By Tumor Type
    • 6.2.4.6.3. By End User
    • 6.2.4.7. Russia
    • 6.2.4.7.1. By Type
    • 6.2.4.7.2. By Tumor Type
    • 6.2.4.7.3. By End User
    • 6.2.4.8. The Netherlands
    • 6.2.4.8.1. By Type
    • 6.2.4.8.2. By Tumor Type
    • 6.2.4.8.3. By End User
    • 6.2.4.9. Rest of Europe
    • 6.2.4.9.1. By Type
    • 6.2.4.9.2. By Tumor Type
    • 6.2.4.9.3. By End User

7. Asia-Pacific Patient-Derived Xenograft (PDX) Model Market

• 7.1. Market Size & Forecast, 2019-2029
  • 7.1.1. By Value (USD Million)
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Tumor Type
  • 7.2.3. By End User
  • 7.2.4. By Country
    • 7.2.4.1. China
    • 7.2.4.1.1. By Type
    • 7.2.4.1.2. By Tumor Type
    • 7.2.4.1.3. By End User
    • 7.2.4.2. India
    • 7.2.4.2.1. By Type
    • 7.2.4.2.2. By Tumor Type
    • 7.2.4.2.3. By End User
    • 7.2.4.3. Japan
    • 7.2.4.3.1. By Type
    • 7.2.4.3.2. By Tumor Type
    • 7.2.4.3.3. By End User
    • 7.2.4.4. South Korea
    • 7.2.4.4.1. By Type
    • 7.2.4.4.2. By Tumor Type
    • 7.2.4.4.3. By End User
    • 7.2.4.5. Australia & New Zealand
    • 7.2.4.5.1. By Type
    • 7.2.4.5.2. By Tumor Type
    • 7.2.4.5.3. By End User
    • 7.2.4.6. Indonesia
    • 7.2.4.6.1. By Type
    • 7.2.4.6.2. By Tumor Type
    • 7.2.4.6.3. By End User
    • 7.2.4.7. Malaysia
    • 7.2.4.7.1. By Type
    • 7.2.4.7.2. By Tumor Type
    • 7.2.4.7.3. By End User
    • 7.2.4.8. Singapore
    • 7.2.4.8.1. By Type
    • 7.2.4.8.2. By Tumor Type
    • 7.2.4.8.3. By End User
    • 7.2.4.9. Vietnam
    • 7.2.4.9.1. By Type
    • 7.2.4.9.2. By Tumor Type
    • 7.2.4.9.3. By End User
    • 7.2.4.10. Rest of APAC
    • 7.2.4.10.1. By Type
    • 7.2.4.10.2. By Tumor Type
    • 7.2.4.10.3. By End User

8. Latin America Patient-Derived Xenograft (PDX) Model Market

• 8.1. Market Size & Forecast, 2019-2029
  • 8.1.1. By Value (USD Million)
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Tumor Type
  • 8.2.3. By End User
  • 8.2.4. By Country
    • 8.2.4.1. Brazil
    • 8.2.4.1.1. By Type
    • 8.2.4.1.2. By Tumor Type
    • 8.2.4.1.3. By End User
    • 8.2.4.2. Mexico
    • 8.2.4.2.1. By Type
    • 8.2.4.2.2. By Tumor Type
    • 8.2.4.2.3. By End User
    • 8.2.4.3. Argentina
    • 8.2.4.3.1. By Type
    • 8.2.4.3.2. By Tumor Type
    • 8.2.4.3.3. By End User
    • 8.2.4.4. Peru
    • 8.2.4.4.1. By Type
    • 8.2.4.4.2. By Tumor Type
    • 8.2.4.4.3. By End User
    • 8.2.4.5. Rest of LATAM
    • 8.2.4.5.1. By Type
    • 8.2.4.5.2. By Tumor Type
    • 8.2.4.5.3. By End User

9. Middle East & Africa Patient-Derived Xenograft (PDX) Model Market

• 9.1. Market Size & Forecast, 2019-2029
  • 9.1.1. By Value (USD Million)
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Tumor Type
  • 9.2.3. By End User
  • 9.2.4. By Country
    • 9.2.4.1. Saudi Arabia
    • 9.2.4.1.1. By Type
    • 9.2.4.1.2. By Tumor Type
    • 9.2.4.1.3. By End User
    • 9.2.4.2. UAE
    • 9.2.4.2.1. By Type
    • 9.2.4.2.2. By Tumor Type
    • 9.2.4.2.3. By End User
    • 9.2.4.3. Qatar
    • 9.2.4.3.1. By Type
    • 9.2.4.3.2. By Tumor Type
    • 9.2.4.3.3. By End User
    • 9.2.4.4. Kuwait
    • 9.2.4.4.1. By Type
    • 9.2.4.4.2. By Tumor Type
    • 9.2.4.4.3. By End User
    • 9.2.4.5. South Africa
    • 9.2.4.5.1. By Type
    • 9.2.4.5.2. By Tumor Type
    • 9.2.4.5.3. By End User
    • 9.2.4.6. Nigeria
    • 9.2.4.6.1. By Type
    • 9.2.4.6.2. By Tumor Type
    • 9.2.4.6.3. By End User
    • 9.2.4.7. Algeria
    • 9.2.4.7.1. By Type
    • 9.2.4.7.2. By Tumor Type
    • 9.2.4.7.3. By End User
    • 9.2.4.8. Rest of MEA
    • 9.2.4.8.1. By Type
    • 9.2.4.8.2. By Tumor Type
    • 9.2.4.8.3. By End User

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Patient-Derived Xenograft (PDX) Model Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Patient-Derived Xenograft (PDX) Model Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 12.1. JSR Corporation
• 12.2. Wuxi Apptec
• 12.3. The Jackson Laboratory
• 12.4. Charles River Laboratories International, Inc.
• 12.5. Taconic Biosciences, Inc.
• 12.6. Oncodesign Precision Medicine
• 12.7. Inotiv, Inc.
• 12.8. Pharmatest Services
• 12.9. Hera BioLabs
• 12.10. EPO Berlin-Buch GmbH
• 12.11. Xentech
• 12.12. Urosphere
• 12.13. Altogen Labs
• 12.14. Abnova Corporation
• 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations